Transitioning Patients With Pulmonary Arterial Hypertension From Parenteral Prostacyclin: One Center's Experience

PURPOSE: Pulmonary arterial hypertension (PAH) is a devastating disease with a variety of treatment options available, depending upon severity and etiology. Patients who are more severely ill receive infusion therapy. There is a paucity of data in the literature on the potential for transitioning patients requiring IV/SQ prostacyclin to alternate therapies. We report our experience transitioning patients with PAH from IV/SQ prostacyclin therapy to oral and/or inhaled therapies.